| Q27015753 | "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control |
| Q92017867 | 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone |
| Q35908392 | A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors |
| Q34060224 | ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice |
| Q92250735 | ABHD6: Its Place in Endocannabinoid Signaling and Beyond |
| Q48663996 | Analysis of γ-aminobutyric acid (GABA) type A receptor subtypes using isosteric and allosteric ligands |
| Q38593114 | Biosynthesis and Fate of Endocannabinoids |
| Q36759329 | Brain 2-Arachidonoylglycerol Levels Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented by Microwave Irradiation |
| Q47134613 | CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity |
| Q39021787 | Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation? |
| Q40594444 | Cannabinoid Receptor 2 Modulates Susceptibility to Experimental Cerebral Malaria through a CCL17-dependent Mechanism |
| Q42700473 | Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms |
| Q59808648 | Cannabinoids and Pain: New Insights From Old Molecules |
| Q38566169 | Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease |
| Q89468008 | Cannabinoids in the descending pain modulatory circuit: Role in inflammation |
| Q45814311 | Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling. |
| Q50653781 | Control of Inhibition by the Direct Action of Cannabinoids on GABAA Receptors. |
| Q88600929 | Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling |
| Q48622819 | Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus. |
| Q42078022 | Do N-arachidonyl-glycine (NA-glycine) and 2-arachidonoyl glycerol (2-AG) share mode of action and the binding site on the β2 subunit of GABAA receptors? |
| Q33785477 | Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model |
| Q46640052 | Effects of unsaturated fatty acids on the kinetics of voltage-gated proton channels heterologously expressed in cultured cells |
| Q38877058 | Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. |
| Q28300390 | Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications |
| Q35754490 | Endocannabinoid signalling and the deteriorating brain |
| Q38185071 | Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions |
| Q37648343 | Endocannabinoids: A Promising Impact for Traumatic Brain Injury. |
| Q36298487 | Evidence for bidirectional endocannabinoid transport across cell membranes |
| Q38593120 | Genetic Manipulation of the Endocannabinoid System |
| Q48606721 | In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). |
| Q90189126 | Inhibitory Plasticity: From Molecules to Computation and Beyond |
| Q64285486 | Interventions after acute stress prevent its delayed effects on the amygdala |
| Q28287173 | Latest advances in the discovery of fatty acid amide hydrolase inhibitors |
| Q44435277 | Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state |
| Q34661028 | Molecular analysis of the site for 2-arachidonylglycerol (2-AG) on the β₂ subunit of GABA(A) receptors |
| Q26998964 | Monoacylglycerol lipase - a target for drug development? |
| Q28535638 | Monoacylglycerols activate TRPV1--a link between phospholipase C and TRPV1 |
| Q47725960 | Neurophysiological evidence for the presence of cannabinoid CB1 receptors in the laterodorsal tegmental nucleus. |
| Q38185075 | No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids |
| Q38135917 | PUFA-derived endocannabinoids: an overview |
| Q38235026 | Pain in neuromyelitis optica--prevalence, pathogenesis and therapy |
| Q92921940 | Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? |
| Q92150126 | Preserving the balance: diverse forms of long-term GABAergic synaptic plasticity |
| Q89125092 | Proceedings of the Epilepsy Foundation's 2017 Cannabinoids in Epilepsy Therapy Workshop |
| Q30467877 | Reversible disruption of pre-pulse inhibition in hypomorphic-inducible and reversible CB1-/- mice. |
| Q38276026 | Rising stars: modulation of brain functions by astroglial type-1 cannabinoid receptors |
| Q58545801 | Stereoselective Synthesis of the Isomers of Notoincisol A: Assigment of the Absolute Configuration of this Natural Product and Biological Evaluation |
| Q37973315 | Sticking out of the crowd: the molecular identity and development of cholecystokinin-containing basket cells |
| Q39631476 | Structural Studies of GABAA Receptor Binding Sites: Which Experimental Structure Tells us What? |
| Q26859328 | Structure, function, and modulation of GABA(A) receptors |
| Q98228200 | Targeting Endocannabinoid Metabolism: an Arrow with Multiple Tips Against Multiple Sclerosis |
| Q53829696 | The Neuroglial Dialog Between Cannabinoids and Hemichannels. |
| Q47618301 | The endocannabinoid system in guarding against fear, anxiety and stress |
| Q34949720 | The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica |
| Q36646602 | Time-coded neurotransmitter release at excitatory and inhibitory synapses |
| Q26862444 | Why do cannabinoid receptors have more than one endogenous ligand? |